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Introduction
The immune system of neonate is completely different
from that from the adults. In cord blood, dendritic cells
(DCs) dominate that mean that neonatal immunologi-
cal response is still immature. The immunological
changes as well as maturation are present before and
just after birth. The birth gives rise to appropriate
response, where DCs contain the first line of the
defense. They are specialized antigen-presenting cells
(APCs). We can distinguish two types of DC: myieloid
(mDC) and lymphoid dendritic cells (pDC). They are
mainly responsible for presenting antigens to naive
lymphocyte T cells. It is said that are also able to
induce immunological tolerance [1-4].
The antigen B7-H1 belongs to the newly discovered
B7 immunomodulatory proteins family and it is a co-
stimulatory protein with properties of inhibiting T-cell
response. It ligates CD28 antigen family and either
interacts with antigen called programmed death-1 (PD-
1), thus the high expression of this molecule may trans-
mit an inhibitory signal reducing T-cells responses. The
molecules – B7 and CD28 are the part of immunoglob-
ulin (Ig) superfamily of type I transmembrane proteins
[5]. The molecule – B7 may interact with both CD28 as
well as with CTLA-4 inhibitory receptors that are pres-
ent on antigen-presenting cells [6].
The molecule B7-H4 is also B7 membrane family
that down-regulates T cells responses. It is able to
inhibit the proliferation of T cells, reduces Th1 and
Th2 cytokine production and cell cycle progression
ligating to its receptor BTLA on T lymphocytes [7].
There are known some cytokines which regulate the
expression of B7-H4 molecule. Interleukin-10 (IL-10)
up-regulates whereas GM-CSF or IL-4 reduce its
expression. It was either shown that overexpression of
this molecule is present on ovarian cancer tissues and
thus it may be used as a marker of tumors [8-10]. 
The aim of our study was to investigate if there is
an expression of co-stimulatory molecules both B7-H1
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 48, No. 4, 2010
pp. 658-662
The expression of B7-H1 and B7-H4 molecules 
on immature myeloid and lymphoid dendritic cells 
in cord blood of healthy neonates
Kludka-Sternik M1, Serafin A1, Darmochwal-Kolarz D2, Radej S1, Rolinski J1,
Leszczynska-Gorzelak B2, Oleszczuk J2
1Department of Clinical Immunology, Medical University of Lublin, Poland
2Department of Obstetrics and Perinatology, Medical University of Lublin, Poland
Abstract: The aim of our study was to estimate both B7-H1 and B7-H4 molecules on immature myeloid and lymphoid den-
dritic cells in umbilical cord blood of healthy neonates in comparison with peripheral blood of healthy adults. Thirty nine
healthy full-term neonates from physiological single pregnancies and 27 healthy adults were included in the study. The
expression of B7-H1 and B7-H4 was revealed using the immunofluorescence method. Statistical analysis was performed
using a non-parametric test (Mann-Whitney U-Test). The percentages of BDCA-1+ dendritic cells with B7-H1 and B7-H4
expressions were significantly higher in peripheral blood of healthy adults (p<0.00003). It was either observed that the per-
centage of BDCA-2+ dendritic cells with the expression of B7-H4 molecules was significantly higher in peripheral blood of
healthy adults in comparison with umbilical cord blood (p<0.02). Decreased percentages of dendritic cells and co-stimula-
tory molecules indicate that neonates have immature immune system. Depletion of co-stimulatory B7-H1 and B7-H4 mol-
ecules enable appropriate development of immune response.
Key words: B7-H1, B7-H4, BDCA-1+, BDCA-2+, cord blood, neonates.
Correspondence: Kludka-Sternik M, Dept. of Clinical 
Immunology, Medical University of Lublin, Poland; 20-950
Lublin, Jaczewskiego Str, 8, Poland; tel./fax.: (+4881) 7187315,
e-mail: magdalenakludka@go2.pl     
and B7-H4 on immature myeloid and lymphoid den-
dritic cells in umbilical cord blood of healthy neonates
in comparison with peripheral blood of healthy adults. 
Material and methods
Patients. The study population included 39 full-term newborns born
from physiological pregnancies. The deliveries took place in the
Department of Obstetrics and Perinatology, Medical University of
Lublin. Blood samples were collected from umbilical cord through-
out labor. The control group comprised of 27 healthy adults. 
Cell preparation. Twenty milliliters of blood were taken from the
study and control groups and collected in heparinized tubes (Polfa,
Warsaw, Poland). Mononuclear cells (MC) were separated on lym-
phocyte separation medium – Gradisol L (Aqua Medica, Poland) and
centrifuged for 20 minutes at 700 × g. Every 107 of MC were incu-
bated with 10 μl of FcR – Blocking Reagent (Miltenyi Biotec, Ger-
many) for 5 minutes in 22 degrees of Celsius to avoid non-specific
binding. Then, cells were labeled with monoclonal antibodies. Five
μl of appropriate antibodies against following antigens: BDCA-1,
BDCA-2, as well as B7-H1, B7-H4 were added to each sample.
After incubation, cells were centrifuged, washed for 5 minutes at 700
× g in 4 degrees of Celsius. Next, cells were analyzed in the flow
cytometer. The following combinations of antibodies were used for
myeloid dendritic cells: anti – BDCA-1 (CD1c) FITC monoclonal
antibody (Miltenyi Biotec, Germany) and anti – CD19 CyChrome
monoclonal antibody (Pharmingen, USA); anti – BDCA-1 (CD1c)
FITC monoclonal antibody (Miltenyi Biotec, Germany), anti-B7-H1
PE monoclonal antibody (AbD Serotec, USA) and anti-CD19
CyChrome monoclonal antibody (Pharmingen, USA); anti – BDCA-
1 (CD1c) FITC monoclonal antibody (Miltenyi Biotec, Germany),
anti-B7-H4 PE (AbD Serotec, USA) and anti-CD19 CyChrome
monoclonal antibody (Pharmingen, USA).
The following combinations of antibodies were used for lym-
phoid dendritic cells: anti – BDCA-2 (Miltenyi Biotec, Germany);
anti – BDCA-2 FITC (Miltenyi Biotec, Germany) and anti- B7-H1
monoclonal antibody PE (AbD Serotec, USA); anti – BDCA-2
FITC monoclonal antibody (Miltenyi Biotec, Germany) and anti-
B7-H4 PE monoclonal antibody (AbD Serotec, USA).
The cell phenotype characterization was performed using a
FACSCalibur equipped with 488-nm argon laser (Becton Dickin-
son, USA) and analyzed with CellQuest Software (Becton Dickin-
son, USA). We collected 300 000 of events in total. Cell debris and
dead cells were excluded from the analysis based on scatter signal.
Ethical issues. The study design was accepted by the local Ethics
Committee. Informed consent from the delivering patients and
healthy adults for blood sampling was obtained.
Statistic analysis. Statistical differences between groups were esti-
mated using a standard non-parametric test (Mann-Whitney U-test).
The results were presented as median and interquartile ranges. Dif-
ferences at p<0.05 were considered as statistically significant. Sta-
tistica 7.1 PL software was applied to statistical analysis.
Results
The expressions of B7H1 and B7H4 co-stimulatory
molecules were present on immature myeloid BDCA-
1+ and lymphoid BDCA-2+ dendritic cells. It was
observed that the percentages of BDCA-1+ dendritic
cells with B7-H1 and B7-H4 molecule expressions
were significantly higher in peripheral blood of
healthy adults when compared to neonates (p<0.0001).
Moreover, the percentages of BDCA-2+ dendritic cells
with the expressions of B7-H4 molecule were signifi-
cantly higher in peripheral blood of healthy adults in
comparison with umbilical cord blood (p<0.02). Fur-
thermore, we noticed that the percentages of both
group of DCs cells were lower in cord blood when
compared to peripheral blood of healthy adults. The
results are presented in the Figs 1, 2, 3, 4 and 5.
Discussion
It is well known that although neonatal immune sys-
tem is developed, it is still immature just after birth.
When fetus grows, many changes have their onset at
that time and then cells become more specialized. In
this study using appropriate gating strategy we identi-
fied BDCA-1+ and BDCA-2+ subsets of dendritic
cells. It may indicate that neonatal immune system is
still under the control of maternal hormones. It was
described that hormones are able to influence on DC
[11-14]. There are works describing that progesterone
is one of the agents that naturally inhibit cell-mediated
immunity. It is capable to modulate a differentiation,
maturation and function of DCs. Progesterone inhibits
immune responses by producing more immature bone
marrow (BM) [11]. Furthermore, progesterone can be
the inducer of Th2 response. Because of the high con-
centration of these hormones in the fetal-maternal
interface, fetus is tolerated by maternal organism.
After birth, a neonate is still under the maternal hor-
mone control, the concentrations of the hormones are
still elevated in umbilical cord blood. This situation
may explain lower levels of BDCA-1+ and BDCA-2+
in cord blood of neonates in comparison with periph-
eral blood of adults. Prostaglandin – PGE2 present in
the maternal-fetal interface can induce the production
of DCs. It is well known that PGE2 polarizes the mat-
uration of mDC into Th2-promoting DCs [15,16].
There were also studies where it was shown that the
levels of cortisol correlated with DCs counts. 
Szabolcs et al. demonstrated in their study that
there was a difference in absolute number of pDCs in
cord blood in comparison with peripheral one. They
observed lower concentrations of pDCs in volunteer
blood in comparison with cord blood. It was also
noticed lower number of mDCs in healthy adults.
Moreover, in cord blood and adult peripheral blood
there were almost twice as many mDCs than pDCs.
However, we did not observe this kind of correlation
[17].
There is a predominance of Th2 type immunity in 
a neonatal immune system. There are works where it
was described that there are higher numbers of pDC in
umbilical cord blood. It was either marked that neona-
tal immune response is impair and therefore the abili-
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Fig. 1. The percentage of BDCA-1+ dendritic cell in cord blood of
healthy neonates (n=39) in comparison with peripheral blood of
healthy adults (n=27). Fig. 2. The percentage of BDCA-2+ den-
dritic cell in cord blood of healthy neonates (n=39) in comparison
with peripheral blood of healthy adults (n=27). Fig. 3. The per-
centage of BDCA-1+ B7-H1+ dendritic cell in cord blood of
healthy neonates (n=39) in comparison with peripheral blood of
healthy adults (n=27). Fig. 4. The percentage of BDCA-1+ B7-
H4+ dendritic cell in cord blood of healthy neonates (n=39) in
comparison with peripheral blood of healthy adults (n=27). 
Fig. 5. The percentage of BDCA-2+ B7-H4+ dendritic cell in cord
blood of healthy neonates (n=39) in comparison with peripheral
blood of healthy adults (n=27).
ty of inducing T CD3+ cells is lower than in adults. In
addition to this, they are not able to stimulate naive T
cell to IFN-γ production [18]. Other authors did not
confirm the predominance of immature lymphoid DCs
in cord blood of healthy neonates [19].
Dendritic cells play a crucial role in both initiating
and down regulating immune response. They are
responsible for presenting antigens to naive T cells,
thus initiate as well as regulate immunological
response. Their role is important not only in primary
responses, but either in immunological tolerance.
Recently, Dzionek et al. described three blood dendrit-
ic cell antigens: BDCA-1 (CD1c), BDCA-2 (CD303)
and BDCA-3 (CD141) which are thought to be mark-
ers for human peripheral blood DCs [20]. We can dis-
tinguish two subsets of these DCs cells: myeloid den-
dritic cells (mDC) CD11c+/CD123-, and lymphoid
dendritic cells (pDC) CD 123brighCD11c-. The antigen
BDCA-1 is expressed on mDCs, whereas BDCA-2
and BDCA-4 on pDCs cells. There was also described
that mDC produce interleukin-12 (IL-12) and induce
Th1, whereas pDCs develop Th2 type response syn-
thesizing interferon (IFN).
To our knowledge, this is the first time study dis-
closed the difference in the expression of B7-H1 as
well as B7-H4 on BDCA-1+ and BDCA-2+ cells in
umbilical cord blood in comparison with healthy
adults. Our findings shown that both co-stimulatory
molecules are highly expressed on either BDCA-1+ or
BDCA-2+ cells in peripheral blood than in umbilical
cord blood. These findings may suggest that low con-
centration of B7-H1 molecule can induce autoimmune
diseases or allergy in neonates. There are findings
describing the role of B7-H1 molecule in peripheral
blood or in placenta. Activated T cells may be inhibit-
ed by this co-stimulator which can bind its receptor
called PD-1 [21]. By blocking these receptors it is pos-
sible to induce autoimmune disease in organs express-
ing B7-H1 antigen. In addition to this, they are also
detectable on transformed cells as well as in various
human cancers. The higher concentration of B7-H1
molecule on DCs in adults underlines its tolerogenic
properties. Conversely, binding PD-L1 with PD-1
receptor on activated T-cells and B-cells may inhibit T-
cell responses in peripheral tissues by inducing apop-
tosis and inhibiting cell-cycle progression [1]. All
those results proved significant role of B7-H1 mole-
cule in self-tolerance. In addition to this, there is a
study where scientists suggest that the expression of
B7H1 on retinal pigment epithelium cells (RPE) plays
an inhibitory role via interaction with T cells [22].
For the first time, we either estimated the expression
of B7-H4 protein on DCs in umbilical cord blood. We
observed higher expressions of this co-stimulatory
molecule on both BDCA-1+ and BDCA-2+ dendritic
cells in peripheral blood of adults in comparison with
umbilical cord blood. The molecule B7-H4 is mainly
responsible for an inhibiting proliferation of CD4+ and
CD8+ T cells and depletes cytokine production. It is
either capable of inducing programmed cell death. In
vitro B7-H4 molecule decreases regulation of T-cells
response [8,9,23,24]. Kryczek et al. marked that regu-
latory T-cells (Treg) can induce the expression of B7-
H4 molecule on different APCs subset via IL-10 pro-
duction. Moreover, it was described that Tregs cells
enable the suppressor activity to APCs via the expres-
sion of B7-H4 molecule [25]. Their findings may
explain why in our results the expressions of this mol-
ecule were higher in peripheral blood of healthy adults.
Some scientists observed the higher expression of
B7-H4 molecule on cancer cells. Like c-erbB-2 or p53
molecular indicate the degree of biological aggressive-
ness of breast cancer [26], the expression of B4-H4
molecule might be clinically useful. The high expres-
sion of this molecule may be useful as a marker for
detection early stages of cancer [9]. In addition to this
Jankowska et al. demonstrated in their study that mat-
uration markers and co-stimulatory molecules on DCs-
pulsed with tumor cell lysate was significantly differ-
ent in comparison with the expressions in the medium
containing only TNF-α [27].
It has been shown that the function of DCs can be
characterized by regulation of co-stimulatory mole-
cules (B7.1, B7.2) and HLA-DR. Moreover immature
DCs are thought to control peripheral tolerance by
inducing the differentiation of human regulatory T
cells (Treg) [28-31]. They are able to induce immune
tolerance under certain conditions [32].
In conclusion, dendritic cells may be involved in
the immune response of newborns. The decreased per-
centages of dendritic cells and co-stimulatory mole-
cules indicate that neonates have immature immune
system. Although the detailed function of co-stimula-
tory molecules in cord blood is still largely unknown,
the lower expression of immunosuppressive B7-H1
molecule may elucidate its tolerogenic properties in
cord blood. Moreover, the depletion of co-stimulatory
B7-H1 and B7-H4 molecules enables appropriate
development of immune response.
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